000			03677nam a22004815i 4500
001			978-0-387-30011-5
003			DE-He213
005			20161121230635.0
007			cr nn 008mamaa
008			100301s2006 xxu| s |||| 0|eng d
020			_a9780387300115 _9978-0-387-30011-5
024	7		_a10.1007/978-0-387-30011-5 _2doi
050		4	_aRC346-429.2
072		7	_aMJN _2bicssc
072		7	_aMED056000 _2bisacsh
082	0	4	_a616.8 _223
245	1	0	_aErythropoietin and the Nervous System _h[electronic resource] : _bNovel Therapeutic Options for Neuroprotection / _cedited by Ahmet Höke.
264		1	_aBoston, MA : _bSpringer US, _c2006.
300			_aXI, 223 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aHistory and Biology of Erythropoietin in Hematopoietic and Non-Neural Tissues -- Expression of Erythropoietin and Its Receptor in the Central Nervous System -- Erythropoietin and Neuroprotection in the Central Nervous System: Intracellular Signaling Pathways -- Regulation of Erythropoietin Expression in the Nervous System: The Hypoxia Inducible Factor -- Erythropoietin Neuroprotection in the Term and Preterm Infant: Safety and Efficacy -- Erythropoietin for the Treatment of Acute Ischemic Stroke: Preclinical Rationale -- Erythropoietin Neuroprotection in the Retina -- Erythropoietin for Treatment of Human Brain Disease: Experience from Proof-of-Concept Trials -- Erythropoietin in Spinal Cord Injury -- Erythropoietin and Neuroprotection in the Peripheral Nervous System: In Vivo Studies -- An Endogenous Pathway Preventing Axonal Degeneration Mediated by Schwann Cell — Derived Erythropoietin -- Role of Erythropoietin in Inflammatory Pathologies of the CNS -- Development of Non-Erythropoietic Erythropoietin Variants for Neuroprotection.
520			_aErythropoietin and the Nervous System is the first book of its kind to bring together researchers from many different disciplines of neuroscience to present a current state-of-the-art review of multiple aspects of erythropoietin research as it relates to the nervous system. Erythropoietin (EPO) is a chemokine hormone that is widely distributed throughout the body. In addition to its traditional role as a hormone that stimulates red blood cell production, in recent years many laboratories have shown that EPO can act as a neuroprotective compound in a variety of injury paradigms in the nervous system. Past experience with the relatively safety profile of this FDA-approved drug makes it an ideal candidate to take into clinical trials for neuroprotection. We are on the verge of major clinical trials using this drug for neuroprotection in diseases ranging from stroke, to transverse myelitis to chemotherapy-induced peripheral neuropathy. This book should stimulate new research on erythropoietin and the nervous system and bring new investigators to the field. It will benefit scientists and clinicians interested in neuroprotection in the broadest sense.
650		0	_aMedicine.
650		0	_aNeurosciences.
650		0	_aNeurology.
650		0	_aNeurosurgery.
650		0	_aPsychiatry.
650	1	4	_aMedicine & Public Health.
650	2	4	_aNeurology.
650	2	4	_aNeurosciences.
650	2	4	_aPsychiatry.
650	2	4	_aNeurosurgery.
700	1		_aHöke, Ahmet. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9780387300108
856	4	0	_uhttp://dx.doi.org/10.1007/978-0-387-30011-5
912			_aZDB-2-SME
950			_aMedicine (Springer-11650)
999			_c501755 _d501755